Search Results for "Colchicine And Rivaroxaban"

17:16 EST 18th January 2017 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Optimal dosing of rivaroxaban is undefined

The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the....

Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.

Rivaroxaban for Postoperative DVT of the Lower Limb

Is rivaroxaban a safe and effective approach to postsurgical deep vein thrombosis after extended, but failed, warfarin therapy? Journal of Medical Case Reports

Treatment with colchicine is not linked to reducing cardiovascular mortality

An evidence review of 39 clinical trials found that patients who received continuous long-term treatment with colchicine had no reduction in all-cause mortality or cardiovascular mortality.

Colchicine and Prevention of Cardiovascular Events

This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials comparing the effects of long-term colchicine treatment with usual care or placebo on cardiovascular events in patients ...

Meta-analysis: Colchicine cuts risk of pericarditis recurrence

(HealthDay)—Colchicine is effective and reduces the risk of pericarditis recurrence/post-pericardiotomy syndrome, according to a meta-analysis published online Aug. 31 in Cardiovascular Therapeutics...

Fewer Major Bleeds on Dabigatran vs Rivaroxaban for AF

In elderly patients with nonvalvular atrial fibrillation (AF), dabigatran and rivaroxaban provide comparable protection against thromboembolic stroke but dabigatran is safer, according to a new analys...

Rivaroxaban: new tool for antiphospholipid syndrome (lupus condition)

Rivaroxaban could be a safe treatment option for antiphospholipid syndrome, an important finding for people with lupus, says research published in The Lancet Haematology. Thrombotic antiphospholipid s...

Matching PubMed Articles

Potential anticancer role of colchicine-based derivatives: an overview.

Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine i...

Colchicine for prevention and treatment of cardiac diseases: a meta-analysis.

Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...

Colchicine in Renal Medicine: New Virtues of an Ancient Friend.

Colchicine is a plant-derived alkaloid that disrupts the cell microtubule system and accumulates in neutrophils, inhibiting neutrophil adhesion and recruitment. Colchicine has been used extensively in...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.

Activated protein C resistance (APC-R) is assessed as part of thrombophilia screening, preferably in patients not taking oral anticoagulants. Rivaroxaban is known to alter some APC-R assays. To our kn...

Search Whole site using Google

Quick Search
Advertisement Advertisement